Page last updated: 2024-11-12
tigapotide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
tigapotide: a synthetic peptide corresponding to amino acids 31-45 of PSP94 (prostate secretory protein) that inhibits matrix metalloproteinase-9 secretion [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16155604 |
| CHEMBL ID | 3040192 |
| MeSH ID | M0493471 |
Synonyms (11)
| Synonym |
|---|
| l-threonine, l-alpha-glutamyl-l-tryptophyl-l-glutaminyl-l-threonyl-l-alpha-aspartyl-l-asparaginyl-l-cysteinyl-l-alpha-glutamyl-l-threonyl-l-cysteinyl-l-threonyl-l-cysteinyl-l-tyrosyl-l-alpha-glutamyl- |
| unii-041y48q3w4 |
| unii-1wz6s45s94 |
| tigapotide |
| tigapotide [inn] |
| pck-3145 |
| 1wz6s45s94 , |
| tigapotide [who-dd] |
| CHEMBL3040192 |
| Q27253002 |
| DTXSID30233869 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "The most common adverse events reported were pain and nausea." | ( Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Armstrong, A; Cowan, R; Daigneault, L; Dulude, H; Fenemore, J; Griffiths, R; Hawkins, RE; Irvine, A; Panchal, C; Sereda, K, 2005) | 0.33 |
| "PCK3145 was safe and well tolerated at all doses." | ( Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Armstrong, A; Cowan, R; Daigneault, L; Dulude, H; Fenemore, J; Griffiths, R; Hawkins, RE; Irvine, A; Panchal, C; Sereda, K, 2005) | 0.33 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The LC-MS/MS and ELISA methods can be applied for monitoring levels of PCK3145 in mouse plasma for in vivo pharmacokinetic and bioavailability animal studies." | ( Development and validation of analytical methodologies for the quantification of PCK3145 and PEG-PCK3145 in mice. Danika, C; El Mubarak, MA; Leontari, I; Sivolapenko, GB, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||